Covid-19
M-A | Clinical risk factors of adverse outcomes among women with COVID-19 in the pregnancy and postpartum period.
28 Sep, 2022 | 13:47h | UTCCommentary: Risk factors among pregnant and postpartum women with COVID-19 – News Medical
Long covid—an update for primary care.
23 Sep, 2022 | 13:10h | UTCLong covid—an update for primary care – The BMJ
RCT | Helmet noninvasive ventilation no better than usual respiratory support for acute hypoxemic respiratory failure due to COVID-19.
22 Sep, 2022 | 13:11h | UTC
Commentary on Twitter
Helmet noninvasive ventilation did not significantly reduce 28-day mortality vs usual respiratory support among patients with acute hypoxemic respiratory failure due to #COVID19 #pneumonia. https://t.co/LCuuY9UqZA #Research pic.twitter.com/NgdzwCVJ4V
— JAMA (@JAMA_current) September 20, 2022
Understanding post-COVID-19 interstitial lung disease: a new fibroinflammatory disease entity.
22 Sep, 2022 | 13:09h | UTC
Commentary on Twitter
Post #COVID19 interstitial lung disease?
🦠 PC-ILD fibroinflammatory disease
🦠 etiopathogenesis
Identifying risk factors & understanding immunopathomechanisms critical to facilitate early intervention to prevent, slow or arrest lung damage progression.
📎https://t.co/OEM2W9bAEd pic.twitter.com/m4w4qUXl9r— Intensive Care Medicine (@yourICM) September 8, 2022
The Lancet Commission on lessons for the future from the COVID-19 pandemic – “a massive global failure.”
16 Sep, 2022 | 13:03h | UTCHomepage: The Lancet COVID-19 Commission
The Lancet Commission on lessons for the future from the COVID-19 pandemic
Editorial: COVID-19: the case for prosociality
Infographic: COVID-19 response: a massive global failure
Commentaries:
WHO responds to The Lancet COVID-19 Commission – World Health Organization
Covid-19: Commission describes “massive global failures” of pandemic response – The BMJ
Lancet Commission on COVID-19 response: ‘Massive global failure’ – CIDRAP
Review | Multisystem inflammatory syndrome in children (MIS-C) and neonates (MIS-N) associated with COVID-19: optimizing definition and management.
14 Sep, 2022 | 13:15h | UTC
Commentary on Twitter
Proposed classification of Multisystem inflammatory syndrome in #neonates (MIS-N)
Clinical features
Treatment and immunological mechanisms#MISC #covid19 #PIMSTS #PedsICU#NeoEBM @DrSBagci #NeoTwitter #Neonatology @DrKenRemy1 @ChrisCarrollMD @lizWWyld https://t.co/tDuM51GMr4 pic.twitter.com/PNobOOzevX— Yonca Bulut M.D. (@yoncabulutmd) September 6, 2022
Under a http://creativecommons.org/licenses/by/4.0/ License
RCT | Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19.
13 Sep, 2022 | 13:16h | UTC
Commentaries on Twitter
Interesting results in the #PANAMO trial of vilobelimab, an anti-C5a antibody, in critically ill ICU patients w/ COVID19.
People on MV (n=386) randomized to vilobelimab vs placebo. Mortality was (maybe) reduced in a subgroup w/ more severe illness…🤔https://t.co/bO5XiRptag
1/ pic.twitter.com/EUNda67T9j— Nick Mark MD (@nickmmark) September 11, 2022
NEW Research—In addition to SOC, vilobelimab improves survival of invasive mechanically ventilated patients w/ #COVID19 and leads to a significant decrease in mortality
Read the PANAMO study from Prof Alexander Vlaar & colleagues here https://t.co/k5UuqQtqyE pic.twitter.com/Xmrb76ZpzW
— The Lancet Respiratory Medicine (@LancetRespirMed) September 8, 2022
RCT | Dipeptidyl peptidase-1 inhibition does not improve outcomes in patients hospitalized with COVID-19.
13 Sep, 2022 | 13:15h | UTC
Commentary on Twitter
NEW Research—Brensocatib treatment did not improve clinical status at day 29 in patients hospitalised with #COVID19
Being presented at #ERSCongress, ALERT 3 session, Sept 5 from 13:15 BST
From @profjdchalmers, @keirholly, @meretelong & colleagueshttps://t.co/Vlqhfs6qtj pic.twitter.com/5CY0LS4Bvy
— The Lancet Respiratory Medicine (@LancetRespirMed) September 5, 2022
Two large clinical trials showed Vitamin D supplements do not reduce the risk of Covid-19.
11 Sep, 2022 | 22:56h | UTCEditorial: Can vitamin D protect against covid-19? – The BMJ
News Release: No link between vitamin D supplements and reduced risk of covid-19 – BMJ Newsroom
Cohort Study | Long-term cardiac pathology in individuals with mild initial COVID-19 illness.
8 Sep, 2022 | 14:44h | UTCLong-term cardiac pathology in individuals with mild initial COVID-19 illness – Nature Medicine
Review | COVID-19 in children.
8 Sep, 2022 | 14:43h | UTCCOVID-19 in Children – Pediatric Clinics of North America
Consensus Statement | Cardiac screening prior to return to play after SARS-CoV-2 infection in the child and adolescent athlete. – “Asymptomatic individuals and those with mild symptoms should be cleared by their primary care or team physician, after physical examination and accurate evaluation of medical history”.
6 Sep, 2022 | 14:36h | UTC
M-A | Safety and efficacy of abacavir for treating infants, children, and adolescents living with HIV.
6 Sep, 2022 | 14:27h | UTC
Commentary on Twitter
*New meta-analysis* supports the use of #abacavir as a preferred first-line regimen for infants & children living with #HIV
By @jujesson & colleagueshttps://t.co/WSvp5ZOUf1 pic.twitter.com/qFBo5O3zJC
— The Lancet Child & Adolescent Health (@LancetChildAdol) September 5, 2022
Perspective | Science, competing values, and trade-offs in public health — the example of Covid-19 and masking.
5 Sep, 2022 | 14:37h | UTC
FDA authorizes updated COVID boosters from Moderna and Pfizer.
5 Sep, 2022 | 14:36h | UTCFDA authorizes updated COVID boosters from Moderna and Pfizer – CIDRAP
FDA News Release: Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose – U.S. Food & Drug Administration
Review | Covid-19 vaccines — immunity, variants, boosters.
1 Sep, 2022 | 11:57h | UTCCovid-19 Vaccines — Immunity, Variants, Boosters – New England Journal of Medicine
Risk of BA.5 infection among persons exposed to previous SARS-CoV-2 variants.
1 Sep, 2022 | 11:56h | UTC
Commentary on Twitter
Conventional wisdom is that previous infection with omicron subvariant BA.1 or BA.2 does notprotect against BA.5, but data from Portugal show considerable protection against BA.5 infection from previous BA.1 or BA.2 infection. https://t.co/1qXPAENSyn pic.twitter.com/qKpbuF2DDu
— NEJM (@NEJM) August 31, 2022
RCT | Outpatient convalescent plasma therapy for high-risk patients with early COVID-19.
31 Aug, 2022 | 11:48h | UTC
#ESCCongress | In critically ill patients with COVID-19, full-dose anticoagulation reduced thrombotic events but increased the risk of bleeding.
30 Aug, 2022 | 12:12h | UTCNews Release: Trial supports full-dose anticoagulation to prevent blood clots in COVID-19 patients – European Society of Cardiology
Related:
Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library
Commentary on Twitter
#OriginalResearch SimPub #ESCCongress: In the #COVID-PACT 2×2 factorial RCT, full-dose prophylactic anticoagulation, but not the addition of clopidogrel, reduced thrombotic complications but w/ increased bleeding among critically-ill patients w/ COVID-19 https://t.co/UNxFCIC5B9 pic.twitter.com/p5LGmpCGeL
— Circulation (@CircAHA) August 29, 2022
Retrospective Cohort Study | Nirmatrelvir use and severe Covid-19 outcomes during the Omicron surge.
25 Aug, 2022 | 12:08h | UTC
Commentary on Twitter
During the clinical rollout of nirmatrelvir in Israel in early 2022, most patients (78%) had previous SARS-CoV-2 immunity. Benefit was seen among patients at highest risk for Covid-19 progression, such as those 65+. https://t.co/O6CxzDdIfH pic.twitter.com/ccCaCCh15i
— NEJM (@NEJM) August 24, 2022
Retrospective Cohort Study | Clinical and genetic risk factors for acute incident venous thromboembolism in ambulatory patients with COVID-19.
24 Aug, 2022 | 14:17h | UTC
Commentary on Twitter
Ambulatory #COVID19 was associated with a substantially increased risk of incident venous thromboembolism, but this risk was greatly reduced in fully vaccinated people with breakthrough infection. https://t.co/98zKNfEWaU #Research
— JAMA Internal Medicine (@JAMAInternalMed) August 18, 2022
Retrospective Cohort Study | Association of COVID-19 vs. Influenza with risk of arterial and venous thrombotic events among hospitalized patients.
24 Aug, 2022 | 14:16h | UTCCommentary: Higher risk of vein blood clots in COVID vs flu patients – CIDRAP
News Release: People with Severe COVID-19 Face Increased Risk of Life-Threatening Blood Clots – Penn Medicine News
Commentary on Twitter
The risk of blood clots in hospitalized patients with Covid vs influenza was increased 60-90% within 90 days, for venous but not arterial thrombosishttps://t.co/wPHf18NYYB @JAMA_current
Retrospective, much smaller influenza cohort from 2018-2019 pic.twitter.com/sClYHF0J6U— Eric Topol (@EricTopol) August 16, 2022
Updated systematic review and critical appraisal: prediction models for diagnosis and prognosis of covid-19.
23 Aug, 2022 | 13:31h | UTCCommentary: Update to living systematic review on prediction models for diagnosis and prognosis of covid-19 – The BMJ
Commentary on Twitter
NEW update in @bmj_latest
606 prognostic models for #COVID19 identified – 29 had low risk of bias, 32 had unclear risk of bias, AND 545 HAD HIGH RISK OF BIAS!
+Poorly reported – use TRIPOD please https://t.co/tVA0xHXdRu#epitwitter #statstwitter pic.twitter.com/n71vdgY8wM
— Gary Collins 🇪🇺 (@GSCollins) August 22, 2022
Risk of myocarditis after sequential doses of COVID-19 vaccine vs. after SARS-CoV-2 infection by age and sex.
23 Aug, 2022 | 13:25h | UTCNews Release: Myocarditis risk significantly higher after COVID-19 infection vs. after a COVID-19 vaccine – Circulation
M-A | Incubation period of COVID-19 caused by unique SARS-CoV-2 strains.
23 Aug, 2022 | 13:24h | UTC